Mark Ruzov1, Gilad Rimon1, Oleg Pikovsky2, David Stepensky1. 1. Department of Clinical Biochemistry and Pharmacology, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva. 2. Blood Bank & Hematology Institute, Soroka University Medical Center, Beer Sheva, Israel.
Abstract
AIMS: The aim of the study was to analyze the interaction between celecoxib and low dose aspirin for COX-1 binding and its consequences on the aspirin-mediated antiplatelet effects. METHODS: We investigated ex vivo the interaction between celecoxib and aspirin for COX-1 binding and measured the resulting antiplatelet effects. We applied mechanism-based pharmacokinetic-pharmacodynamic (PKPD) modelling to analyze these data and to predict in vivo platelet aggregation for different doses and administration schedules of aspirin and celecoxib. RESULTS: The predictions of the PK-PD model were consistent with results from previous studies that investigated interaction between aspirin and celecoxib. The modelling results indicate that celecoxib can attenuate to a limited extent the in vivo antiplatelet effects of low dose aspirin. The extent of this interaction can be substantial (up to 15% increase in platelet aggregation by 200 mg day(-1) celecoxib when combined with low dose aspirin) during the first days of aspirin administration in patients who are already treated with celecoxib, and it cannot be prevented by separate administration of the interacting drugs. CONCLUSIONS: At the recommended therapeutic doses, celecoxib can attenuate to a limited extent the in vivo antiplatelet effects of low dose aspirin. Patients receiving a combination of low dose aspirin and the recommended doses of celecoxib were not identified to have increased risk of cardiovascular and cerebrovascular events due to competition between these drugs for COX-1 binding. Interaction between low dose aspirin and other COX-2 inhibitors and its clinical consequences requires further investigation.
AIMS: The aim of the study was to analyze the interaction between celecoxib and low dose aspirin for COX-1 binding and its consequences on the aspirin-mediated antiplatelet effects. METHODS: We investigated ex vivo the interaction between celecoxib and aspirin for COX-1 binding and measured the resulting antiplatelet effects. We applied mechanism-based pharmacokinetic-pharmacodynamic (PKPD) modelling to analyze these data and to predict in vivo platelet aggregation for different doses and administration schedules of aspirin and celecoxib. RESULTS: The predictions of the PK-PD model were consistent with results from previous studies that investigated interaction between aspirin and celecoxib. The modelling results indicate that celecoxib can attenuate to a limited extent the in vivo antiplatelet effects of low dose aspirin. The extent of this interaction can be substantial (up to 15% increase in platelet aggregation by 200 mg day(-1) celecoxib when combined with low dose aspirin) during the first days of aspirin administration in patients who are already treated with celecoxib, and it cannot be prevented by separate administration of the interacting drugs. CONCLUSIONS: At the recommended therapeutic doses, celecoxib can attenuate to a limited extent the in vivo antiplatelet effects of low dose aspirin. Patients receiving a combination of low dose aspirin and the recommended doses of celecoxib were not identified to have increased risk of cardiovascular and cerebrovascular events due to competition between these drugs for COX-1 binding. Interaction between low dose aspirin and other COX-2 inhibitors and its clinical consequences requires further investigation.
Authors: F Catella-Lawson; M P Reilly; S C Kapoor; A J Cucchiara; S DeMarco; B Tournier; S N Vyas; G A FitzGerald Journal: N Engl J Med Date: 2001-12-20 Impact factor: 91.245
Authors: B Rocca; F Santilli; D Pitocco; L Mucci; G Petrucci; E Vitacolonna; S Lattanzio; D Mattoscio; F Zaccardi; R Liani; N Vazzana; A Del Ponte; E Ferrante; F Martini; C Cardillo; R Morosetti; M Mirabella; G Ghirlanda; G Davì; C Patrono Journal: J Thromb Haemost Date: 2012-07 Impact factor: 5.824
Authors: Giulia Renda; Stefania Tacconelli; Marta L Capone; Daniele Sacchetta; Francesco Santarelli; Maria G Sciulli; Marco Zimarino; Marilena Grana; Elisabetta D'Amelio; Maria Zurro; Thomas S Price; Carlo Patrono; Raffaele De Caterina; Paola Patrignani Journal: Clin Pharmacol Ther Date: 2006-09 Impact factor: 6.875
Authors: T Ohmori; Y Yatomi; T Nonaka; Y Kobayashi; S Madoiwa; J Mimuro; Y Ozaki; Y Sakata Journal: J Thromb Haemost Date: 2006-06 Impact factor: 5.824